Omeros Corporation Announces 2024 Annual Meeting of Shareholders

TL;DR

<b>Omeros Corporation invites shareholders to its virtual 2024 Annual Meeting on June 6, 2024, to vote on director elections, executive compensation, and auditor ratification.</b>

AI Summary

OMEROS CORP (OMER) filed a Proxy Statement (DEF 14A) with the SEC on April 29, 2024. Omeros Corporation will hold its 2024 Annual Meeting of Shareholders virtually via live webcast on June 6, 2024, at 10:00 a.m. Pacific time. Shareholders can attend, vote, and submit questions online at www.virtualshareholdermeeting.com/OMER2024. The meeting agenda includes electing three Class III director nominees, approving executive compensation, and ratifying the appointment of Ernst & Young LLP as independent auditor. The company encourages shareholders to vote by telephone, internet, or proxy card prior to the meeting. Gregory A. Demopulos, M.D., Chairman and CEO, expressed appreciation for shareholder support.

Why It Matters

For investors and stakeholders tracking OMEROS CORP, this filing contains several important signals. This virtual format allows for broader shareholder participation regardless of location. The meeting will cover key corporate governance matters, including the election of directors and approval of executive compensation, which directly impact company strategy and shareholder value.

Risk Assessment

Risk Level: low — OMEROS CORP shows low risk based on this filing. The filing is a routine proxy statement for an annual shareholder meeting, with no immediate financial or operational disclosures that would significantly alter the company's risk profile.

Analyst Insight

Shareholders should review the director nominees and executive compensation proposals before the June 6, 2024 meeting to cast an informed vote.

Key Numbers

• June 6, 2024 — Annual Meeting Date (2024 Annual Meeting of Shareholders)
• 10:00 a.m. Pacific time — Meeting Time (2024 Annual Meeting of Shareholders)
• Three — Director Nominees (Class III director nominees to be elected)
• 2027 — Director Term End (Director term until the 2027 Annual Meeting)

Key Players & Entities

• OMEROS CORP (company) — Registrant
• Gregory A. Demopulos, M.D. (person) — Chairman and CEO
• Ernst & Young LLP (company) — independent registered public accounting firm
• June 6, 2024 (date) — 2024 Annual Meeting date
• 2024 (date) — Fiscal year

FAQ

Risk Factors

• General Corporate Governance [low — regulatory]: The company is subject to standard corporate governance regulations and requirements as a publicly traded entity.

Industry Context

Omeros Corporation operates in the pharmaceutical preparations industry, focusing on developing and commercializing therapies.

Regulatory Implications

As a publicly traded company, Omeros Corporation is subject to the Securities Exchange Act of 1934 and related SEC regulations governing proxy solicitations and annual meetings.

What Investors Should Do

1. Review the proxy statement for details on director nominees and their qualifications.
2. Understand the advisory resolution on executive compensation and its implications.
3. Confirm the ratification of Ernst & Young LLP as the independent auditor.

Key Dates

• 2024-06-06: 2024 Annual Meeting of Shareholders — Shareholders will vote on director nominees, executive compensation, and auditor ratification.
• 2024-04-29: Filing Date — Definitive Proxy Statement filed.

Glossary

DEF 14A

Definitive Proxy Statement filed with the SEC. (This filing type indicates the company is providing formal notice and details for its annual shareholder meeting.)

Proxy Statement

A document providing information to shareholders about matters to be voted on at a company meeting. (Essential for shareholders to make informed voting decisions on corporate matters.)

Year-Over-Year Comparison

This is a routine DEF 14A filing for the annual shareholder meeting, providing information on upcoming votes and not containing new financial performance data compared to previous filings.

Key Financial Figures

• $0.01 — ares of Omeros' common stock, par value $0.01 per share, were issued and outstanding.
• $15,000 — at an anticipated cost in the range of $15,000 to $30,000. 2024 PROXY STATEMENT / 5
• $30,000 — cipated cost in the range of $15,000 to $30,000. 2024 PROXY STATEMENT / 5 "Householdi
• $200 million — eholders. In early 2023, we received a $200 million payment due from Rayner as a result of
• $46.3 million — lly, Rayner paid during 2023 a total of $46.3 million in royalties on their U.S. net sales of
• $33.3 million — s of OMIDRIA. We retained approximately $33.3 million of these royalties after paying to DRI
• $13 million — s LP (DRI) the maximum capped amount of $13 million due for 2023 under the royalty monetiza
• $126.0 million — gement with DRI. We previously received $126.0 million in cash upon execution of the royalty m
• $115.5 million — which we received an upfront payment of $115.5 million in exchange for the right to receive th
• $27.5 m — DRI two milestone payments, each up to $27.5 million, payable in January 2026 and Janu
• $6.7 million — Drug Abuse awarded Omeros a three-year, $6.7 million grant to pursue development of our lead

Filing Documents

• omer20240424_def14a.htm (DEF 14A) — 768KB
• cancelmosig.jpg (GRAPHIC) — 4KB
• chair.jpg (GRAPHIC) — 1KB
• comp01.jpg (GRAPHIC) — 34KB
• comp02.jpg (GRAPHIC) — 31KB
• demopulossig.jpg (GRAPHIC) — 3KB
• internet.jpg (GRAPHIC) — 2KB
• logo.jpg (GRAPHIC) — 8KB
• mail.jpg (GRAPHIC) — 2KB
• member.jpg (GRAPHIC) — 1KB
• omer20240424_def14aimg020.jpg (GRAPHIC) — 1KB
• phone.jpg (GRAPHIC) — 1KB
• proxy01.jpg (GRAPHIC) — 109KB
• proxy02.jpg (GRAPHIC) — 160KB
• 0001437749-24-013762.txt (&nbsp;) — 1261KB

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 24 TRANSACTIONS WITH RELATED PERSONS 43

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 44 DELINQUENT SECTION 16(a) REPORTS 45 PROPOSAL 3 — RATIFICATION OF THE APPOINTMENT OF OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM 46 OTHER BUSINESS 48 2024 PROXY STATEMENT / 1 OMEROS CORPORATION The Omeros Building 201 Elliott Avenue West Seattle, Washington 98119 INFORMATION CONCERNING PROXY SOLICITATION, VOTING AND THE MEETING General Information The enclosed proxy is solicited on behalf of the board of directors of Omeros Corporation for use at the 2024 Annual Meeting of Shareholders (the 2024 Annual Meeting) of Omeros Corporation to be held on Thursday, June 6, 2024, at 10:00 a.m. Pacific time, or any adjournment or postponement thereof, for the purposes set forth herein and in the accompanying Notice of Annual Meeting of Shareholders. The 2024 Annual Meeting will be held virtually via live webcast on the Internet at www.virtualshareholdermeeting.com/OMER2024. This proxy statement, the enclosed proxy and the 2023 Annual Report to Shareholders, which includes audited financial statements as of and for the year ended December 31, 2023, will be mailed on or about April 29, 2024 to all shareholders entitled to vote at the 2024 Annual Meeting. Record Date and Quorum Shareholders of record at the close of business on April 18, 2024, which we refer to as the record date, are entitled to notice of and to vote their shares at the 2024 Annual Meeting. As of the record date, 57,944,159 shares of Omeros' common stock, par value $0.01 per share, were issued and outstanding. Holders of shares of common stock are entitled to cast one vote per share on all matters to be voted on at the 2024 Annual Meeting. The presence in person or by proxy of the holders of record of a majority of the outstanding shares of common stock entitled to vote is required to constitute a quorum for the transaction of business at the 2024 Annual Meeting. Abstentions and broker non-votes (which occur when

View Full Filing

View this DEF 14A filing on SEC EDGAR